935 0 Kommentare Avid Bioservices to Make Three Presentations at IBC's Biopharmaceutical Development and Production Week Conference Highlighting Its Innovative Applications for Developing Purification Methods and Quantitative Analytical Assays to Achieve and Monitor Manuf - Seite 2

"Increasing the consistency of manufacturing processes is critical for our clients. This is achieved by better understanding the critical process parameters, including the materials used during production and by making adjustments that do not effect critical process characteristics," said Gene Yoshioka, senior director of manufacturing for Avid Bioservices. "One of the case studies being presented demonstrates the potential impact that raw material quality can have on cGMP production. Through better process understanding, we are able to achieve consistent process performance and a high level of quality for the products delivered to our clients."

In addition, Avid Bioservices will host conference attendees in booth #114 in the exhibition hall Monday, March 30^th - Thursday, April 2^nd.

For more information on IBC's Biopharmaceutical Development & Production Week Conference, please visit: http://www.ibclifesciences.com/BDPWeek/overview.xml

About Avid Bioservices

Avid Bioservices provides a comprehensive range of high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, final product filling, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.